Implanet’s Jazz sales up 18% in 2016
​ Implanet published its 2016 sales, confirming the good dynamics of its marketing activity (+18% compared to 2015, from €6.7 M to €7.8 M). The company benefits from the growing adoption of its lead product, the Jazz Band, especially in France and the US. Given the company’s efforts to further accelerate the adoption of Jazz, we believe that the company has the means to maintain this trend in 2017. Although the reported sales are slightly below our forecast, we remain confident on the company's outlook and maintain our target price at € 2.34 / share.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.